Vetoquinol SA
PAR:VETO
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Vetoquinol SA
Long-Term Investments
Vetoquinol SA
Long-Term Investments Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Long-Term Investments | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Vetoquinol SA
PAR:VETO
|
Long-Term Investments
€1.5m
|
CAGR 3-Years
13%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
8%
|
|
|
Sanofi SA
PAR:SAN
|
Long-Term Investments
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Ipsen SA
PAR:IPN
|
Long-Term Investments
€171.3m
|
CAGR 3-Years
8%
|
CAGR 5-Years
6%
|
CAGR 10-Years
15%
|
|
|
Virbac SA
PAR:VIRP
|
Long-Term Investments
€48.5m
|
CAGR 3-Years
117%
|
CAGR 5-Years
51%
|
CAGR 10-Years
13%
|
|
|
Boiron SA
PAR:BOI
|
Long-Term Investments
€16.5m
|
CAGR 3-Years
41%
|
CAGR 5-Years
40%
|
CAGR 10-Years
18%
|
|
|
Medincell SA
PAR:MEDCL
|
Long-Term Investments
€5.3m
|
CAGR 3-Years
18%
|
CAGR 5-Years
9%
|
CAGR 10-Years
N/A
|
|
Vetoquinol SA
Glance View
Vétoquinol SA operates as a global animal health company. The company is headquartered in Lure, Bourgogne-Franche-Comte. The company went IPO on 2006-11-16. The Company’s product portfolio is divided between livestock, such as cattle and pigs, and companion animals, including dogs and cats. Vetoquinol SA’s offering includes anti-infectives, such as Marbocyl; anti- pain inflammatories, which comprise Tolfedine, intended for dogs and cats, and Tolfine for livestock, and cardiovascular and nephrology treatment, such as Prilium, an oral daily administration formula for dogs, among others. The firm markets over 700 products, in such countries as France, Austria, Canada, Italy, Poland, Spain and the Netherlands, among others. The company trades its products throughout Europe, North America, Africa, the Middle East and Pacific Asia. In April 2014, it acquired Bioniche's animal health business.
See Also
What is Vetoquinol SA's Long-Term Investments?
Long-Term Investments
1.5m
EUR
Based on the financial report for Jun 30, 2025, Vetoquinol SA's Long-Term Investments amounts to 1.5m EUR.
What is Vetoquinol SA's Long-Term Investments growth rate?
Long-Term Investments CAGR 10Y
8%
Over the last year, the Long-Term Investments growth was -10%. The average annual Long-Term Investments growth rates for Vetoquinol SA have been 13% over the past three years , -6% over the past five years , and 8% over the past ten years .
